CN116782896A - 硝化裸盖菇素衍生物及其用于调节5-ht2a受体和治疗精神障碍的用途 - Google Patents

硝化裸盖菇素衍生物及其用于调节5-ht2a受体和治疗精神障碍的用途 Download PDF

Info

Publication number
CN116782896A
CN116782896A CN202180068083.6A CN202180068083A CN116782896A CN 116782896 A CN116782896 A CN 116782896A CN 202180068083 A CN202180068083 A CN 202180068083A CN 116782896 A CN116782896 A CN 116782896A
Authority
CN
China
Prior art keywords
alkyl
group
hydrogen atom
compound
nitro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180068083.6A
Other languages
English (en)
Chinese (zh)
Inventor
吉利恩·M·哈格尔
彼得·J·法基尼
林长春
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nvirick Biosciences Canada Co
Original Assignee
Nvirick Biosciences Canada Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nvirick Biosciences Canada Co filed Critical Nvirick Biosciences Canada Co
Publication of CN116782896A publication Critical patent/CN116782896A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16—Tryptamines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1025—Acyltransferases (2.3)
    • C12N9/1029—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/10—Nitrogen as only ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y203/00—Acyltransferases (2.3)
    • C12Y203/01—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
    • C12Y203/01005—Arylamine N-acetyltransferase (2.3.1.5)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y401/00—Carbon-carbon lyases (4.1)
    • C12Y401/01—Carboxy-lyases (4.1.1)
    • C12Y401/01028—Aromatic-L-amino-acid decarboxylase (4.1.1.28), i.e. tryptophane-decarboxylase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y402/00—Carbon-oxygen lyases (4.2)
    • C12Y402/01—Hydro-lyases (4.2.1)
    • C12Y402/0102—Tryptophan synthase (4.2.1.20)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN202180068083.6A 2020-09-02 2021-09-02 硝化裸盖菇素衍生物及其用于调节5-ht2a受体和治疗精神障碍的用途 Pending CN116782896A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063073534P 2020-09-02 2020-09-02
US63/073,534 2020-09-02
PCT/CA2021/051214 WO2022047583A1 (en) 2020-09-02 2021-09-02 Nitrated psilocybin derivatives and use thereof for modulating 5-ht2a receptor and for treating a psychiatric disorder

Publications (1)

Publication Number Publication Date
CN116782896A true CN116782896A (zh) 2023-09-19

Family

ID=80492288

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180068083.6A Pending CN116782896A (zh) 2020-09-02 2021-09-02 硝化裸盖菇素衍生物及其用于调节5-ht2a受体和治疗精神障碍的用途

Country Status (10)

Country Link
US (1) US20230040398A1 (https=)
EP (1) EP4208446A4 (https=)
JP (1) JP2023539390A (https=)
KR (1) KR20230061473A (https=)
CN (1) CN116782896A (https=)
AU (1) AU2021336667A1 (https=)
CA (1) CA3191095A1 (https=)
IL (1) IL301028A (https=)
MX (1) MX2023002619A (https=)
WO (1) WO2022047583A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114787363A (zh) 2019-10-01 2022-07-22 恩派瑞安神经科学公司 对真菌进行遗传工程化以调节色胺表达
EP4291549A4 (en) 2021-02-12 2025-01-22 Enveric Biosciences Canada Inc. MULTISUBSTITUENT PSILOCYLYBINDER DERIVATIVES AND METHODS OF USE
EP4457336A4 (en) 2021-12-31 2026-01-14 Empyrean Neuroscience Inc ORGANISMS GENETICALLY MODIFIED TO PRODUCE PSYCHOTROPIC ALKALOIDS
WO2023168023A1 (en) 2022-03-04 2023-09-07 Reset Pharmaceuticals, Inc. Co-crystals or salts comprising psilocin
US12065404B2 (en) 2022-03-18 2024-08-20 Enveric Biosciences Canada Inc. C4-carboxylic acid-substituted tryptamine derivatives and methods of using
EP4493544A4 (en) * 2022-03-18 2026-03-04 Enveric Biosciences Canada Inc TRYPTAMINE DERIVATIVE SALTS SUBSTITUTED WITH C4-CARBOXYLIC ACID AND C4-CARBONOTHIOATE AND METHODS OF USE
KR20250097973A (ko) * 2022-11-18 2025-06-30 인베릭 바이오사이언시스 캐나다 인크. 치환된 n-프로필아민 융합 헤테로사이클릭 메스칼린 유도체

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999064044A1 (en) * 1998-06-08 1999-12-16 Advanced Medicine, Inc. Novel therapeutic agents that modulate 5-ht receptors
CN1450896A (zh) * 2000-07-28 2003-10-22 印斯拜尔药品股份有限公司 用吲哚衍生物降低眼内压的方法
CN1610547A (zh) * 2001-03-29 2005-04-27 伊莱利利公司 用作5－ht6受体拮抗剂的n－(2－芳乙基)苄胺
WO2018081456A1 (en) * 2016-10-26 2018-05-03 University Of Florida Research Foundation, Incorporated Highly active self-sufficient nitration biocatalysts

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2172415B2 (es) * 2000-07-28 2003-11-16 Univ Madrid Complutense Tratamiento del glaucoma y la hipertension ocular por medio de un analogo de la melatonina.
EP1747779A1 (en) * 2005-07-28 2007-01-31 Laboratorios Del Dr. Esteve, S.A. Tetrahydro-b-carbolin-sulfonamide derivatives as 5-HT6 ligands
CN103601662B (zh) * 2013-11-21 2016-04-06 深圳市药品检验所 一种褪黑素半抗原、褪黑素完全抗原及其制备方法和应用
WO2015140799A1 (en) * 2014-03-18 2015-09-24 Carmel-Haifa University Economic Corp. Ltd Methods for improving cognitive function via modulation of quinone reductase 2
WO2018106907A1 (en) * 2016-12-08 2018-06-14 Novatarg, Inc. Fused bicyclic alkylene linked imidodicarbonimidic diamides, methods for synthesis, and uses in therary
US20200147038A1 (en) * 2017-04-20 2020-05-14 Eleusis Benefit Corporation, Pbc Assessing and treating psychedelic-responsive subjects
US10640508B2 (en) * 2017-10-13 2020-05-05 Massachusetts Institute Of Technology Diazene directed modular synthesis of compounds with quaternary carbon centers

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999064044A1 (en) * 1998-06-08 1999-12-16 Advanced Medicine, Inc. Novel therapeutic agents that modulate 5-ht receptors
CN1450896A (zh) * 2000-07-28 2003-10-22 印斯拜尔药品股份有限公司 用吲哚衍生物降低眼内压的方法
CN1610547A (zh) * 2001-03-29 2005-04-27 伊莱利利公司 用作5－ht6受体拮抗剂的n－(2－芳乙基)苄胺
WO2018081456A1 (en) * 2016-10-26 2018-05-03 University Of Florida Research Foundation, Incorporated Highly active self-sufficient nitration biocatalysts

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
AURORA FINE CHEMICALS 等提供的产品目录: "STN检索报告", 《数据库REGISTRY（在线）》, 8 July 2020 (2020-07-08), pages 1 - 8 *
BRUCE E. BLOUGH ET AL.: "Alpha-ethyltryptamines as dual dopamine–serotonin releasers", 《BIOORGANIC & MEDICINAL CHEMISTRY LETTERS》, vol. 24, no. 19, 29 July 2014 (2014-07-29), pages 4754 - 4758, XP029064422, DOI: 10.1016/j.bmcl.2014.07.062 *
FABIENNE PEYROT ET AL.: "Nitrosation of N-Terminally Blocked Tryptophan and Tryptophan- Containing Peptides by Peroxynitrite", 《CHEMBIOCHEM》, vol. 8, 20 December 2006 (2006-12-20), pages 217 - 223, XP055911501, DOI: 10.1002/cbic.200600385 *
J. B. MCKAY ET AL.: "ANALOGUES OF PSILOCIN AND LYSERGIC ACID DIETHYLAMIDE I. CHLORO, NITRO, AND AMINO DERIVATIVES OF 3-SUBSTITUTED INDOLES", 《CANADIAN JOURNAL OF CHEMISTRY》, vol. 41, 31 December 1963 (1963-12-31), pages 2585 - 2590, XP055911511, DOI: 10.1139/v63-378 *
JORG HOLENZ ET AL.: "Medicinal Chemistry Driven Approaches Toward Novel and Selective Serotonin 5-HT6 Receptor Ligands", 《J. MED. CHEM.》, vol. 48, no. 6, 31 December 2005 (2005-12-31), pages 1781 - 1795, XP002993846, DOI: 10.1021/jm049615n *
L. KH. VINOGRAD ET AL.: "INDOLE DERIVATIVES.126. SUBSTITUTED NITROTRYPTAMINES", 《CHEM. HETEROCYCL. CMOPD.》, vol. 20, 30 September 1984 (1984-09-30), pages 984 - 988 *
RINAT F. SALIKOV ET AL.: "Synthesis and cytotoxic properties of tryptamine derivatives", 《BIOORGANIC & MEDICINAL CHEMISTRY LETTERS》, 27 June 2015 (2015-06-27), pages 3597, XP029249455, DOI: 10.1016/j.bmcl.2015.06.070 *
VERONIQUE LECLERC ET AL.: "Synthesis of Nitroindole Derivatives with High Affinity and Selectivity for Melatoninergic Binding Sites MT3", 《J. MED. CHEM.》, vol. 45, no. 9, 31 December 2002 (2002-12-31), pages 1853 - 1859, XP002350181, DOI: 10.1021/jm011053+ *

Also Published As

Publication number Publication date
AU2021336667A1 (en) 2023-03-30
EP4208446A4 (en) 2024-10-30
US20230040398A1 (en) 2023-02-09
CA3191095A1 (en) 2022-03-10
IL301028A (en) 2023-05-01
AU2021336667A8 (en) 2023-04-13
JP2023539390A (ja) 2023-09-13
KR20230061473A (ko) 2023-05-08
EP4208446A1 (en) 2023-07-12
WO2022047583A1 (en) 2022-03-10
MX2023002619A (es) 2023-04-10

Similar Documents

Publication Publication Date Title
CN116782896A (zh) 硝化裸盖菇素衍生物及其用于调节5-ht2a受体和治疗精神障碍的用途
US20250057861A1 (en) Halogenated psilocybin derivatives and methods of using
CN106068325B (zh) 手性设计
US20230086396A1 (en) Glycosylated psilocybin derivatives and methods of using
WO2022047580A1 (en) Hydroxylated psilocybin derivatives and methods of using
CN114057692A (zh) 一种杂环类化合物、其制备方法及用途
CN112481233B (zh) 制备胞二磷胆碱用酶制剂以及酶催化制备胞二磷胆碱的方法
JP2017061492A (ja) ボアカンギンからノルイボガインを調製するための方法および組成物
WO2004113300A1 (ja) 新規三環性複素環化合物
US11008570B2 (en) 3′ end caps for RNAi agents for use in RNA interference
ES2816005T3 (es) Tratamientos de combinación que comprenden imidazopirazinonas para el tratamiento de trastornos psiquiátricos y/o cognitivos
WO2014069520A1 (ja) 新規修飾核酸
WO2017044569A1 (en) Heterocyclic constrained tricyclic sulfonamides as anti-cancer agents
TW201625629A (zh) 新穎吡咯并嘧啶化合物或其鹽，及含有其之醫藥組成物，特別是基於ｎａｅ抑制作用的腫瘤等之預防劑及／或治療劑
CN111849845B (zh) 全细胞催化生产5-氨基戊酸的工程菌及5-氨基戊酸的制备方法
TW201540305A (zh) ５’末端具有非天然核苷酸之寡核苷酸
US20260103442A1 (en) Aminated psilocybin derivatives and methods of using
CA2523238A1 (en) Amino-pyranoquinolines as serotonin reuptake inhibitors and 5-htia receptor agonists
WO2025143262A1 (ja) カルバモイルエチル修飾を含有する二本鎖ｒｎａ
HK40101010A (zh) 用於制备双环酮化合物的方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20230919